异体CIK细胞治疗放化疗后肝癌患者的临床观察

Clinical trial of heterogeneous cytokine induced killer （CIK） cells for the patients with liver cancer after radiotherapy or chemotherapy

目的观察异体细胞因子诱导的杀伤细胞（CIK细胞）治疗放化疗后肝癌患者的临床疗效。方法对32例放化疗后肝癌患者进行异体CIK细胞治疗，同时选取32例健康成人为对照组。观察治疗前后外周血免疫指标的变化及其与对照组的比较。比较CIK细胞治疗前后患者肝功能、甲胎蛋白及腹同等指标的变化。结果CIK细胞治疗后，CD3＋、CD4＋T细胞百分牢上升，CD8＋T细胞百分率下调，CD4＋／CD8＋比值上调，较放化疗后有明显改善（P〈0．05），腹围明显缩小（P〈0．05）；各项生化指标较治疗前有明显改善（P〈0．05）。结论异体CIK细胞治疗安全、可行，可提高放化疗后肝癌患者的免疫功能，减轻肝细胞损伤，改善临床症状，改善生活质量。

Objective To observe the clinical effect after the treatment of heterogeneous cytokine induced killer （CIK） cells for patients with live cancer after radiotherapy or chemotherapy. Methods 32 patients with liver cancer after radiotherapy or chemotherapy were treated by CIK cells, and 32 healthy adults were chosen in the control. The immunity indexes, enzymes of liver and α -fetoprotein （AFP） in the peripheral blood and abdomen circumference had been compared before and after CIK eells being transfused. Results After CIK cells therapy, the percentage of CD3 ＋ , CD4 ＋ T cells rose ; the percentage of CD8 ＋ T declined ; the ratio of CD4 ＋/CD8 ＋ rose （ P 〈 0. 05 ） ; the abdomen circumference deflated （ P 〈 0. 05） ; The enzymes of liver and a - fetoprotein （AFP） in the peripheral blood declined. Conclusion Heterogeneous CIK cells treatment is safe and feasible. It may improve the immunity and quality of life, and decrease the damage of liver cells.